House-dust mite allergy immunotherapy - Lofarma

Drug Profile

House-dust mite allergy immunotherapy - Lofarma

Alternative Names: Dermatophagoides injective allergoid - Lofarma; Lais® Mites Sublingual Tablets

Latest Information Update: 26 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Lofarma S.p.A
  • Developer Ajou University School of Medicine; Lofarma S.p.A
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis

Most Recent Events

  • 22 May 2017 Lofarma initiates enrolment in a phase II trial for Allergic rhinoconjunctivitis in Germany (EudraCT2016-003439-39)
  • 15 Mar 2016 Phase-II development is ongoing in Germany
  • 20 Oct 2014 Ajou University School of Medicine plans a phase IV trial for Allergic rhinoconjunctivitis in South Korea (NCT02277483)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top